Polyherbal oil Kyzyl May® in complex therapy of some visceral diseases.
V.M. Boborykin
1 Department of Internal Medicine at Kazakh Physicians’ Continuing Education Institute (head of the chair professor V.A. Polosukhina)
Treatment of many chronic visceral diseases is still a difficult task for therapists. Despite the significant progress in studying aetiopathogenesis, new medicines and treatment methods the incidence doesn’t decrease. Therapists know that the number of backsets of such diseases as chronic bronchitis, ulcer disease, chronic gastritis, and duodenitis doesn’t decrease. There are a lot of reasons for the current situation; among them the progressing ecological trouble, loss of body defenses, change of nutrition at the considerable part of population. Lowering of the level of sanitarian culture in connection with insufficient health education, irregular supply with medicines, etc.
In this regard, the positive fact is the development and application of new balsamic medical product Kyzyl May on the basis of local raw materials. The medical product was tested in the clinic in 1991 – 1993 under the name “ZPM-7” (St. John’s wort polyherbal oil). Originally it was planned to study its efficiency in complex therapy of patients with chronic bronchitis. The reason for carrying out clinical tests was the fact that many Kyzyl May components influence different factors of chronic bronchitis pathogenesis, in particular, the infection value, malfunction of respiratory epithelial clearance, immune status in case of chronic bronchitis, obstruction of bronchial tubes, and also the activation of lipid peroxidation were considered (N.R. Paleev and co-authors M, 1985). The composition of Kyzyl May oil provided the impact on the specified pathogenesis links of chronic bronchitis. The flavonoids and phytoncides of hypericum, balm, and nettle containing in it, provided antibacterial action; essential oils of brier, thyme, licorice promote the restoration of normal respiratory epithelial clearance and render broncholytic effect (I.P. Zamotayev, 1993). Immunomodulatory action is caused by the content of licorice, sea buckthorn, and brier in the medical product. Fatty-acid composition of the medical product possesses antioxidant characteristics (G.P. Pavelkovsky, 1993). The vitamins containing in the medical product Kyzyl May are of broad spectrum.
The main group (I) for clinical tests consisted of 18 people with chronic obstructive bronchitis aged from 38 till 52 years. Men – 15 (83,3%), women – 3 (16,7%) of patients. Check group (II) – 20 patients with chronic obstructive bronchitis similar to the main group on age-sex composition. The main symptoms in clinic were: cough (100%), sputum discharge (100% of the patients), labored breathing (88,9% in the main and 85,0% in check group), fervescence (22,2% in the main and 20,0% in check group). Clinical symptoms of obstructive bronchitis (syndrome), in particular, prolonged expiration and dry rales while exhalation were found at all the patients of both groups; pulmonary emphysema – at 3 patients in the 1st and at 4 patients in the 2nd groups. Suppurative phlegm – in 12 patients in the main and in 13 patients in control group. All the patients were put on standard therapy: bronchial spasmolytics, expectorant, antibacterial agents for the main indications, physiotherapy. Besides, the patients of the 1st group were prescribed Kyzyl May: 1 teaspoon per os 3 times a day, treatment course – 10 – 12 days.
In case of the assessment of patients’ state dynamics it has been revealed that cough became rarer in both groups on the 4-6th day, sputum discharge was lightened in the 1st group on the 3-4th day, in the 2nd group on the 6-7th day. Purulence in phlegm disappeared on the 6-7th day in the 1st and 10-11th day in the check group respectively, also body temperature was normalized. Labored breathing and other signs of obstructive syndrome were liquidated at the patients of the 1st group on 4-5th day, and 2nd group on the 7-8th day.
The study of after history of Kyzyl May medical product wasn’t planned; however, some patients of the 1st group, who were admitted to the central city clinical hospital in 1994, noticed more fixed and prolonged remission after the course of administration of polyherbal oil. In our opinion, it is connected both with immunomodulatory effect of Kyzyl May components and with reparative properties of sea buckthorn and brier contained in the medical product.
We also carried out clinical tests of polyherbal oil in a small group of patients with ulcer disease and chronic gastroduodenitis. The patients were prescribed 1 tablespoon of the medical product 4-5 times a day in 50 – 60 minutes before meals. Due to the small number of group (8 people) and its non-uniformity it is impossible to carry out statistical processing, mathematical analysis of the data received. However, it is possible to mention that taking Kyzyl May promoted faster pain and dyspeptic syndrome management. Possibly, it is connected to spasmolytic and local anesthetic properties of the medical product, its ability to improve regeneration processes of gastric mucosa and sedative effect (I.E. Akopov, 1986).
All the patients, who received Kyzyl May polyherbal oil, mentioned its pleasant taste and high tolerability. There were no side effects, only in one case the patient with chronic astroduodenitis attack had the symptoms of loosening and acceleration of evacuation up to 3 times per day. However, it is impossible to connect it to taking Kyzyl May, because similar symptoms may be caused by simultaneous taking of antacids.
Besides, we were afraid of allergy development and avoided to prescribe the tested medical product to the patients, who had pollinosisor hay asthma in their anamnesis. The possibility of their development can’t be excluded, considering the complex composition of Kyzyl May including flowers (pollen, respectively) of many plants.
Thus, Kyzyl May polyherbal oil possesses a wide range of pharmacological properties providing it a worthy place in complex therapy of chronic diseases of respiratory system and digestive tract. The medical product components are used in etiotropic, pathogenetic and symptomatic treatment of chronic bronchitis, gastroduodenitis and ulcer disease. Efficiency, availability and high tolerability of Kyzyl May allow recommending it for wide use while treatment of the above mentioned diseases.
The data received allow us to expand the circle of indications to use Kyzyl May polyherbal oil in different clinical directions. To crown the message, it is necessary to tell once again that there were recorded no serious negative effects, including allergic.
